Senzo Health has developed the Amplified Lateral Flow (ALF) platform, which provides PCR-accurate diagnostics for infectious diseases with results available in under 10 minutes and at a significantly lower cost than traditional laboratory tests. This technology addresses the need for rapid, accessible testing in both clinical and home settings, enabling earlier diagnosis and treatment of prevalent diseases.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional PCR-based diagnostics for infectious diseases require specialized laboratory equipment and trained personnel, leading to delays in obtaining results and limiting accessibility, particularly in point-of-care and home settings. Current lateral flow tests offer rapid results but often lack the sensitivity and accuracy of PCR tests, compromising diagnostic reliability.
Solution
Senzo Health's Amplified Lateral Flow (ALF) platform provides rapid, point-of-care diagnostics for infectious diseases with PCR-level accuracy. The ALF technology enhances the sensitivity of traditional lateral flow assays, enabling detection of low viral loads with results available in under 10 minutes. This allows for earlier and more frequent testing, facilitating timely treatment decisions and improved patient outcomes. The platform's simplicity and affordability make it suitable for use in diverse settings, including clinics, homes, and resource-limited areas, expanding access to accurate and timely diagnostics.
Target Audience
The primary target audience includes healthcare providers, clinical laboratories, and individuals seeking rapid and accurate diagnostic testing for infectious diseases in point-of-care, at-home, and resource-limited settings.
Features
- Amplified Lateral Flow (ALF) technology for enhanced sensitivity and PCR-accurate results
- Rapid results available in under 10 minutes, enabling immediate clinical decision-making
- Point-of-care testing format eliminates the need for laboratory infrastructure and specialized personnel
- Compatibility with a range of infectious disease targets, including COVID-19, HIV, Flu A/B, Hepatitis C, Tuberculosis, and C. Difficile
- Affordable testing solution, reducing the cost barrier for widespread diagnostic adoption
- Simple test procedure suitable for both professional and at-home use